企業プロフィール
Merck 株価・ニュース・カタリスト
- ティッカー:
- MRK
- 取引所:
- NYSE
- セクター:
- Oncology, Immunotherapy, Vaccines
- 所在地:
- United States
株価パフォーマンス
143.81 USD (-1.03%)
終値
最終更新: 2026年10月1日
286B USD
時価総額
株価変動の要因
2026年10月1日 時点で MRK は 1.03% 下落し、$143.81 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Diversified Human and Animal Health Company
Merck, known as MSD outside the United States and Canada, is a global biopharmaceutical company with businesses in prescription medicines, vaccines, and animal health. Its human-health research spans oncology, infectious disease, vaccines, cardiometabolic and respiratory disease, immunology, neuroscience, and ophthalmology.
Oncology and the KEYTRUDA Franchise
Oncology is anchored by KEYTRUDA and subcutaneous KEYTRUDA QLEX, which are used across a broad range of solid tumors and hematologic malignancies. Merck is extending the franchise through earlier-stage treatment, perioperative regimens, and combinations with antibody-drug conjugates and targeted therapies. Its broader oncology pipeline includes sacituzumab tirumotecan, the personalized cancer vaccine intismeran autogene, KRAS inhibitor calderasib, and BCR::ABL1 inhibitor MK-4208.
Vaccines and Infectious Diseases
Merck has a large vaccine franchise spanning human papillomavirus, pneumococcal disease, respiratory syncytial virus, and other infectious diseases. The HIV portfolio combines approved daily treatment with investigational weekly and monthly approaches, including once-weekly islatravir and lenacapavir and once-monthly oral PrEP candidate alimatravir.
Cardiometabolic and Respiratory Medicines
The cardiometabolic portfolio includes WINREVAIR for pulmonary arterial hypertension and LIPFENDRA, an oral PCSK9 inhibitor for hypercholesterolemia. The acquisition of Verona Pharma added OHTUVAYRE for chronic obstructive pulmonary disease, expanding Merck's presence in respiratory medicine alongside a pipeline of cardiovascular and metabolic programs.
Immunology Pipeline
Merck is developing tulisokibart, an anti-TL1A antibody, across ulcerative colitis and other immune-mediated diseases. The program is part of a broader effort to build an immunology franchise through internally developed biologics and externally sourced assets that target inflammatory pathways with potential applications across gastrointestinal, dermatologic, and systemic autoimmune disorders.
Animal Health Business
Merck Animal Health markets medicines, vaccines, identification technologies, and health-management products for livestock and companion animals. The business provides an additional source of diversification and has expanded through acquisitions such as TARGAN, which added automated poultry vaccination and biodevice capabilities.
今後のカタリスト
- Planned global regulatory submissions for the once-weekly oral islatravir/lenacapavir HIV treatment regimen following positive Phase 3 ISLEND-1 and ISLEND-2 results.
- Presentation of full Phase 2 results for tulisokibart in hidradenitis suppurativa at an upcoming medical meeting.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。